If deep brain stimulation (DBS) can help people with Parkinson’s disease walk and speak again, could it help people with Alzheimer’s disease, too? It’s a natural question, and one that ...

In a real-world study, infusion-related reactions occurred in 37% of Alzheimer's patients treated ... Overall, 29 people (15%) had ARIA with brain edema or effusion (ARIA-E) -- with or without ...

Studies suggesting that certain viral infections may influence the onset of Alzheimer's disease are gaining ... of HSV-1 infection on microglia, the brain's immune cells. Using various ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease ... But side effects -- brain swelling and bleeding ...

The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown ... But side effects—brain swelling and bleeding—emerged during clinical trials that ...

An MRI showing Alzheimer’s disease in the brain. Image source: Atthapon/Adobe One key factor is insulin resistance, which affects the brain’s ability to process energy. By shifting to a ...

That ratio is then linked to the presence or absence of amyloid plaques in the brain to determine whether a patient is showing signs of Alzheimer's disease. More than 91% of nearly 500 cognitively ...

Amyloid plaque, a feature of Alzheimer's disease, accumulates outside neurons. A new blood test, Lumipulse, measures two subtypes of tau and amyloid proteins, of which certain levels can predict the ...

The test, developed by Japan-based Fujirebio Diagnostics, uses a blood sample to detect the presence of plaques in the brain called amyloid that are thought to be linked to Alzheimer’s.

A ratio of those proteins tends to correlate with the occurrence or absence of amyloid plaques in the brain, which are among the hallmarks of Alzheimer’s disease. The test does not measure ...